The survival and the long-term trends of patients with gastric cancer in Shanghai, China by Leizhen Zheng et al.
Zheng et al. BMC Cancer 2014, 14:300
http://www.biomedcentral.com/1471-2407/14/300RESEARCH ARTICLE Open AccessThe survival and the long-term trends of patients
with gastric cancer in Shanghai, China
Leizhen Zheng1*, Chunxiao Wu2, Pan Xi1, Meiling Zhu1, Li Zhang1, Siyu Chen1, Xiaoping Li1, Jianchun Gu1
and Ying Zheng2*Abstract
Background: Gastric cancer remains a major health issue and a leading cause of death worldwide. This study
presented a long-term survival data of gastric cancer registered in Shanghai of China from 1972–2003, with aims to
describe the trends as well as the age, sex, stage and tumor sites specific characteristics.
Methods: The main source of information on cancer cases was the notification card sending to the registry. The
residential status of cancer cases was confirmed by home-visits. The methods of follow-up have been a mixture of
both active and passive ones.
Results: We observed an increased trend of survival probability during the last decades. Patients diagnosed during
1972–1976 had a 5-years relative survival rate at 12% for males and 11% for females, respectively, which had
dramatically increased to 30% for male and 32% for female patients respectively during the period of 2002–2003.
Among the patients diagnosed in 2002–2003, the overall survival probability declined with patient’s age at the time
of diagnosis. The lowest survival rate was observed among the oldest group, with the median survival time of
0.8 years. Patients diagnosed with stage I had a higher relative survival rate. Patients with cardia cancer had the
worst prognosis, with the 5-year relative survival rate of 29%.
Conclusions: The survival probability of patients with gastric cancer in Shanghai has improved significantly during
the last decades. Age, stage and site of tumor have an impact on prognosis.Background
Gastric cancer is one of the most common cancers world-
wide, accounting for about 8% of all new cancer cases [1].
In recent decades, the morbidity and mortality of gastric
cancer have fallen down dramatically, with the decline first
taking place in the countries with low incidence while the
decline in the regions with high incidence was relatively
slow [2-4]. Compared with the steady decrease in the
United States and European countries, the incidence of
gastric cancer remains high in the Far East areas, where
up to 100 cases per 100000 populations are reported an-
nually [4]. Despite an overall decrease of incident gastric
cancer has been observed in China, the decline was less
dramatic than other countries and even there was an in-
crease in the youngest and oldest groups [5].* Correspondence: zhengleizhen2006@126.com; yzheng@scdc.sh.cn
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reproduction in any medium, provided the orIn recent years, prognosis of patients with gastric cancer
has improved significantly [6]. Like other health indices,
information on survival statistics is an important compo-
nent in monitoring cancer control activities, which may
suggest possible reasons for the variations and provide
targets for the improvement towards them. Based on the
registry database of gastric cancer in Shanghai of China
since 1970s, we performed the current descriptive study.
The aim of this study is to present the survival data and to
illuminate relevant trends as well as the age, sex, stage of
disease and tumor sites specific characteristics.
Methods
Shanghai is situated on the bank of the Yangtz River Delta
of Eastern China, which is the largest city in China and
the eighth largest city in the world, with a population of
14.0 million (2010 year-end registered population). It in-
cludes urban and suburb areas, where the urban covers 9
districts locating in the center of the municipality, and the
suburb covers the other 9 districts. The data of gastricLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Cancer Registry Center (SCRC), compiled by the Shanghai
Center for Disease Control and Prevention (CDC). The
SCRC was established in the 1960s, which has been
contributing data to the quinquennial IARC publication
Cancer Incidence in Five Continents since Vol. IV [7]. The
main source of information on cancer cases was the notifi-
cation card consisting of basic information for cancer
registration that was sent to the SCRC. The residential sta-
tus of cancer cases was confirmed by home-visits [7]. We
obtained the follow-up data of gastric cancer patients di-
agnosed in 2002–2003 for survival trend analysis, as well
as previous published survival data of the other four
periods (1972–1976, 1980–1984, 1988–1991, and 1992–
1995) which were referred to the “Cancer incidence, mor-
tality and survival rates in urban Shanghai (1973–2000)”
[8] and “Cancer survival in Shanghai, China (1992–1995)
[9]. We identified the gastric cancer cases using the 10th
Revision of the International Classification of Diseases
(code C16) [10]. The cancer registry has been using
AJCC/UICC TNM staging system in combination with
the clinical stages classification system (I-IV).
Patients reported to SCRC were followed up for con-
firmed diagnosis and survival. The methods of follow-up
have been a mixture of both active and passive ones.
With passive follow-up, information on death is rou-
tinely obtained from the death certificates in the vital
statistical section of Shanghai CDC. Through this ap-
proach, patients whose death information has not been
received may be considered to be “alive” until that point
of time. Furthermore, the mortality data are periodically
matched with the incident database of cancers. The vital
status of the unmatched incident cases is then verified
by home visits or postal/telephone enquiries. Active
follow-up is necessary in the absence of reliable health
information. Reports of deaths from hospitals, living sta-
tus from the community, or loss to follow-up were up-
dated until December 31, 2010. The censor was defined
as still alive at the closing date, or lost to follow-up or
died by other causes other than gastric cancer. The sur-
vival probability was estimated using random censoring
data. In the study, a total of 61140 gastric cancer cases
were included for the above-mentioned five periods
(Additional file 1: Table S1), among which 10909 cases
were registered during the period of 2002 to 2003. The
study was approved by the Ethical Review Committee at
Shanghai Municipal CDC [11].
Both observed and relative survival probabilities were
estimated. Life tables were constructed to calculate the
cumulative probability of survival at time ti+1 from the
conditional probabilities of survival during consecutive
intervals of follow-up time up to and including ti+1.
Relative survival is a measure of net survival calculated
by comparing observed survival with expected survivalfrom a comparable set of people that do not have can-
cer. It is used to measure the excess mortality that is as-
sociated with a cancer diagnosis, and is designed to
exclude the effect arising from different background
mortalities. The relative survival (Ri) for a group of pa-
tients at the end of an interval beginning at time ti was
defined as Ri ¼ SiSi , where Si was the absolute survival for
subjects with a gastric cancer and Si
* was the expected
survival of a group of individuals with the same demo-
graphic characteristics (age, and sex, etc.) who were at
risk of death only from causes other than the cancer
under study. Chi-Square test was used to compare the
distribution between males and females. Furthermore,
Log rank test was used to compare the survival rates
with 95% confidence interval (CI). Written informed
consent was obtained from the patient for the publica-
tion of this report and any accompanying images.
Results
As showed in Table 1, there were 10909 newly diagnosed
gastric cancer cases reported during 2002–2003, including
47.1% living in the urban and 52.9% living in the suburb.
Among them, there were 7038 (64.5%) males and 3871
(35.5%) females. Patients aged 65–84 years accounted for
more than 58% of all cases.The proportion of patients be-
ing classified as stage I to IV was 5.5%, 9.9%, 12.4%, and
13.8% respectively, while 58.4% of cases were reported
with “unknown stage”. The gender difference of tumor
sites was significant (χ2 = 79.41, P < 0.001). Malignant neo-
plasm of pyloric antrum account for 22.3% and 4796
(44.0%) cases were reported with unspecified sites. At the
time of the last follow-up (December 31, 2010), 8365
(76.7%) patients died, 2312 (21.2%) patients were alive,
and 232 (2.1%) cases were lost to follow up.
Overall survival rate
Among gastric cancer patients diagnosed during the
period 2002–2003 in Shanghai, the 1-year observed sur-
vival rate was 51% for male and 52% for female, respect-
ively. The 5-years observed survival rate decreased to
25% for male and 27% for female, respectively. The
1-year relative survival rate was 54% for male and 56%
for female patients, respectively. The 5-years relative sur-
vival rate was 30% for male and 32% for female patients,
respectively. The median survival time was 1.09 years.
Patients living in the urban had slightly higher survival
rate compared with the patients in the suburb (Table 2).
Age-specific survival rate
Table 3 showed the survival rate of gastric cancer at dif-
ferent ages. We excluded the cases younger than 35 years
or older than 85 years for survival analysis because of
insufficient number of cases at these age groups. In
Table 1 General information of patients with gastric cancer during 2002–2003 in Shanghai, China
Variables Total Male Female χ2# P
Area
Urban 5139 (47.1) 3270 (46.5) 1869 (48.3) 3.32 0.068
Suburb 5770 (52.9) 3768 (53.5) 2002 (51.7)
Age-group
15- 107 (1.0) 45 (0.6) 62 (1.6) 125.18 <0.001
35- 541 (5.0) 292 (4.1) 249 (6.4)
45- 1625 (14.9) 1032 (14.7) 593 (15.3)
55- 1720 (15.8) 1220 (17.3) 500 (12.9)
65- 3545 (32.5) 2367 (33.6) 1178 (30.4)
75- 2881 (26.4) 1828 (26.0) 1053 (27.2)
85+ 490 (4.5) 254 (3.6) 236 (6.1)
Tumor site*
C16.0 1371 (12.6) 1005 (14.3) 366 (9.5) 79.41 <0.001
C16.1 171 (1.6) 119 (1.7) 52 (1.3)
C16.2 873 (8.0) 536 (7.6) 337 (8.7)
C16.3 2436 (22.3) 1545 (22.0) 891 (23)
C16.4 106 (1.0) 67 (1.0) 39 (1.0)
C16.5 758 (6.9) 527 (7.5) 231 (6)
C16.6 62 (0.6) 30 (0.4) 32 (0.8)
C16.8 336 (3.1) 222 (3.2) 114 (2.9)
C16.9 4796 (44.0) 2987 (42.4) 1809 (46.7)
Stage
I 601 (5.5) 394 (5.6) 207 (5.3) 8.371 0.079
II 1085 (9.9) 721 (10.2) 364 (9.4)
III 1353 (12.4) 902 (12.8) 451 (11.7)
IV 1504 (13.8) 982 (14.0) 522 (13.5)
Unknown 6366 (58.4) 4039 (57.4) 2327 (60.1)
Vital status
Died 8365 (76.7) 5454 (77.5) 2911 (75.2) 7.96 0.019
Survival 2312 (21.2) 1445 (20.5) 867 (22.4)
Lost to follow up 232 (2.1) 139 (2.0) 93 (2.4)
*C16.0, Malignant neoplasm of cardia; C16.1, Malignant neoplasm of fundus of stomach; C16.2, Malignant neoplasm of body of stomach; C16.3, Malignant
neoplasm of pyloric antrum; C16.4, Malignant neoplasm of pylorus; C16.5, Malignant neoplasm of lesser curvature of stomach, unspecified; C16.6, Malignant
neoplasm of greater curvature of stomach, unspecified; C16.8, Malignant neoplasm of overlapping sites of stomach; C16.9, Malignant neoplasm of
stomach, unspecified.
#Chi-Square test was used to compare the distribution between males and females.
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increase of patient’s age at the time of diagnosis. The
lowest survival rate was observed among the oldest
group (75–84 years), with the median survival time of
0.8 years. The age related trend of survival rate was dif-
ferent between male and female patients. For male pa-
tients, the youngest group (35–44 years) had the highest
survival rate with the longest median survival time of
2.3 years. However, the survival probability at 35–44
years age group was worse than those aged 45–64 years
among female gastric patients (Table 3).Stage of disease and survival rate
Patients were classified into different clinical stages
(I-IV) according to AJCC /UICC TNM staging system,
where the lower stage indicated the early clinical phase
of the disease. Based on the survival data from SCRC,
it was obvious that patients diagnosed with lower
stages had significantly better prognosis. The 5-years
relative survival rate was over 80% among patients at
the stage I. However, it dramatically decreased to 10%
when patients were diagnosed at stage IV. The 5-years
relative survival rate of males is slightly higher than
Table 2 Survival rate of patients with gastric cancer in different regions during 2002–2003 in Shanghai, China
Area Sex N Observed survival rate [% (95% CI)] Relative survival rate [% (95% CI)] Median
survival
(years)
1 year 2 years 3 years 4 years 5 years 1 year 2 years 3 years 4 years 5 years
Total 10909 51 (50–52) 37 (36–38) 31 (30–32) 28 (27–29) 26 (25–27) 55 (54–56) 41 (40–42) 35 (34–36) 32 (31–33) 30 (29–31) 1.09
Whole city Male 7038 51 (50–52) 37 (36–38) 30 (29–31) 27 (26–28) 25 (24–26) 54 (53–55) 40 (39–41) 34 (33–35) 31 (30–32) 30 (29–31) 1.06
Female 3871 52 (50–54) 38 (36–40) 32 (31–34) 30 (29–31) 27 (26–28) 56 (54–58) 42 (40–44) 37 (36–39) 34 (33–36) 32 (31–34) 1.14
χ2* 1.05 2.14 6.29 10.09 6.42 - - - - -
P* 0.305 0.144 0.012 0.001 0.011 - - - - -
Urban Total 5139 52 (51–53) 38 (37–39) 32 (31–33) 28 (27–29) 26 (25–27) 56 (55–57) 42 (41–43) 36 (35–37) 33 (32–34) 31 (30–32) 1.13
Male 3270 51 (49–53) 37 (35–39) 30 (28–32) 27 (25–29) 25 (24–27) 55 (53–57) 41 (39–43) 35 (33–37) 32 (30–34) 31 (29–33) 1.07
Female 1869 53 (51–55) 40 (38–42) 34 (32–36) 31 (29–33) 28 (26–30) 58 (56–60) 45 (43–47) 39 (37–41) 36 (34–38) 33 (31–35) 1.24
χ2* 2.02 6.67 6.29 8.65 3.77 - - - - -
P 0.155 0.010 0.012 0.003 0.052 - - - - -
Suburb Total 5770 51 (50–52) 36 (35–37) 30 (29–31) 27 (26–28) 26 (25–27) 54 (53–55) 39 (38–40) 33 (32–34) 31 (30–32) 30 (29–31) 1.05
Male 3768 51 (49–53) 37 (35–39) 30 (29–32) 27 (26–28) 25 (24–26) 54 (52–56) 40 (38–42) 33 (32–35) 31 (30–33) 29 (28–31) 1.05
Female 2002 51 (49–53) 36 (34–38) 31 (29–33) 29 (27–31) 27 (25–29) 55 (53–57) 39 (37–41) 35 (33–37) 33 (31–35) 31 (29–33) 1.05
χ2* 0.01 0.21 1.11 2.48 2.70 - - - - -
P* 0.954 0.645 0.292 0.115 0.100 - - - - -

















Table 3 Survival rate of patients with gastric cancer at different ages during 2002–2003 in Shanghai, China
Age
(years)
Sex N Observed survival rate [% (95% CI)] Relative survival rate [% (95% CI)] Median
survival
(years)
1 year 2 years 3 years 4 years 5 years 1 year 2 years 3 years 4 years 5 years
35-44 Male 292 66 (60–71) 52 (46–58) 46 (40–52) 44 (38–50) 43 (37–49) 66 (60–72) 52 (46–58) 47 (41–53) 45 (39–51) 44 (38–50) 2.3
Female 249 62 (56–68) 51 (45–57) 43 (37–49) 40 (34–46) 39 (33–45) 62 (56–68) 51 (45–57) 44 (38–51) 40 (34–47) 40 (34–47) 2.1
45-54 Male 1032 66 (63–69) 52 (49–55) 45 (42–48) 42 (39–45) 41 (38–44) 66 (63–69) 52 (49–55) 46 (43–49) 44 (41–47) 43 (40–46) 2.3
Female 593 67 (63–71) 54 (50–58) 48 (44–52) 45 (41–49) 43 (39–47) 67 (63–71) 54 (50–58) 49 (45–53) 46 (42–50) 44 (40–48) 2.7
55-64 Male 1220 59 (56–62) 45 (42–48) 38 (35–41) 35 (32–38) 33 (30–36) 60 (57–63) 46 (43–49) 40 (37–43) 38 (35–41) 37 (34–40) 1.7
Female 500 61 (57–65) 48 (44–52) 42 (38–46) 41 (37–45) 38 (34–42) 61 (57–65) 48 (44–53) 44 (40–49) 42 (38–47) 41 (37–46) 1.8
65-74 Male 2367 52 (50–54) 37 (35–39) 30 (28–32) 26 (24–28) 24 (22–26) 54 (52–56) 40 (38–42) 34 (32–36) 33 (31–35) 35 (33–37) 1.1
Female 1178 56 (53–59) 41 (38–44) 34 (31–37) 31 (28–34) 28 (25–31) 56 (53–59) 43 (40–46) 37 (34–40) 36 (33–39) 35 (32–38) 1.4
75-84 Male 1828 37 (35–39) 23 (21–25) 17 (15–19) 14 (12–16) 12 (11–14) 40 (38–42) 29 (27–31) 26 (24–28) 28 (26–30) 34 (32–36) 0.8

















Table 4 Survival rate of patients with gastric cancer in different stages during 2002–2003 in Shanghai, China
Stage Sex N Observed survival rate [% (95% CI)] Relative survival rate [% (95% CI)] Median
survival
(years)
1 year 2 years 3 years 4 years 5 years 1 year 2 years 3 years 4 years 5 years
I Male 394 88 (84–91) 80 (76–84) 73 (68–77) 69 (64–73) 68 (63–73) 91 (88–94) 85 (81–88) 83 (79–87) 84 (80–88) 88 (85–91) >5
Female 207 90 (85–94) 80 (74–85) 74 (67–80) 71 (64–77) 67 (60–73) 93 (89–96) 85 (79–90) 81 (75–86) 82 (76–87) 81 (75–86) >5
II Male 721 79 (76–82) 64 (60–67) 55 (51–59) 51 (47–55) 48 (44–52) 81 (78–84) 69 (65–72) 63 (59–67) 63 (59–67) 64 (60–68) 4.38
Female 364 78 (73–82) 66 (61–71) 58 (53–63) 53 (48–58) 50 (45–55) 81 (77–85) 70 (65–75) 64 (59–69) 61 (56–66) 61 (56–66) 4.91
III Male 902 59 (56–62) 41 (38–44) 31 (28–34) 27 (24–30) 25 (22–28) 62 (59–65) 45 (42–48) 36 (33–39) 34 (31–37) 35 (32–38) 1.51
Female 451 62 (57–66) 42 (37–47) 35 (31–40) 31 (27–36) 29 (25–33) 64 (60–69) 44 (39–49) 39 (35–44) 36 (32–41) 36 (32–41) 1.58
IV Male 982 27 (24–30) 15 (13–17) 11 (9–13) 8 (6–10) 7 (6–9) 29 (26–32) 17 (15–20) 13 (11–15) 11 (9–13) 10 (8–12) 0.68
Female 522 28 (24–32) 15 (12–18) 11 (9–14) 9 (7–12) 8 (6–11) 29 (25–33) 17 (14–21) 13 (10–16) 11 (8–14) 10 (8–13) 0.69
Unknown Male 4039 46 (44–48) 32 (31–33) 26 (25–27) 23 (22–24) 21 (20–22) 50 (49–52) 37 (36–39) 33 (32–35) 33 (32–35) 34 (33–36) 0.93

















Table 5 Survival rate of patients with gastric cancer in different tumor sites during 2002–2003 in Shanghai, China
Tumor sites Sex N Observed survival rate [% (95% CI)] Relative survival rate [% (95% CI)] Median
survival
(years)
1 year 2 years 3 years 4 years 5 years 1 year 2 years 3 years 4 years 5 years
C16.0 Cardia Male 1005 49 (46–52) 33 (30–36) 24 (21–27) 20 (18–23) 18 (16–21) 52 (49–55) 37 (34–40) 30 (27–33) 28 (25–31) 29 (26–32) 1.0
Female 366 53 (48–58) 34 (29–39) 26 (22–31) 23 (19–28) 21 (17–26) 57 (52–62) 39 (34–44) 32 (27–37) 30 (25–35) 29 (24–34) 1.1
C16.1 Fundus Male 119 53 (44–62) 43 (34–52) 38 (29–47) 31 (23–40) 29 (21–38) 55 (45–64) 47 (38–56) 44 (35–53) 40 (31–50) 41 (32–51) 1.3
Female 52 67 (52–79) 53 (39–67) 47 (33–61) 45 (31–59) 43 (30–57) 70 (55–81) 58 (43–71) 54 (40–68) 55 (41–70) 57 (43–71) 2.5
C16.2 Body Male 536 55 (51–59) 39 (35–43) 32 (28–36) 29 (25–33) 27 (23–31) 57 (53–61) 43 (39–47) 37 (33–41) 37 (33–41) 38 (34–42) 1.3
Female 337 58 (53–63) 45 (40–50) 38 (33–43) 34 (29–39) 31 (26–36) 60 (55–65) 47 (42–52) 41 (36–46) 39 (34–44) 37 (32–43) 1.6
C16.3 Pyloric antrum Male 1545 60 (58–62) 44 (42–47) 37 (35–39) 33 (31–35) 31 (29–33) 64 (62–66) 50 (48–53) 45 (42–48) 44 (42–47) 45 (43–48) 1.6
Female 891 59 (56–62) 46 (43–49) 39 (36–42) 37 (34–40) 34 (31–37) 63 (60–66) 51 (48–54) 45 (42–48) 45 (42–48) 45 (42–48) 1.7
C16.4 Pylorus Male 67 71 (58–81) 55 (42–67) 49 (37–61) 44 (32–57) 41 (29–54) 77 (66–87) 62 (50–74) 59 (47–72) 58 (46–70) 59 (47–72) 2.8
Female 39 69 (52–82) 59 (42–74) 54 (38–70) 49 (33–65) 46 (30–62) 73 (55–85) 64 (47–79) 62 (45–77) 60 (42–74) 62 (45–77) 3.7
C16.5 Lesser curvature Male 527 74 (70–78) 60 (56–64) 53 (49–57) 50 (46–54) 47 (43–51) 76 (72–80) 64 (60–68) 60 (56–64) 60 (56–64) 61 (57–65) 3.9
Female 231 72 (66–78) 57 (50–63) 54 (47–61) 50 (43–57) 46 (39–53) 75 (69–80) 61 (54–67) 59 (52–65) 57 (51–64) 57 (51–64) 3.9
C16.6 Greater curvature Male 30 77 (58–90) 53 (34–71) 40 (23–59) 40 (23–59) 40 (23–59) 81 (61–92) 59 (41–77) 47 (28–66) 51 (31–69) 55 (37–75) 2.2
Female 32 71 (52–85) 52 (34–70) 48 (30–66) 48 (30–66) 48 (30–66) 78 (60–91) 58 (41–76) 57 (38–74) 60 (41–76) 65 (47–81) 2.4
C16.8 Overlapping sites Male 222 48 (41–55) 29 (23–36) 24 (19–30) 21 (16–27) 20 (15–26) 50 (43–57) 33 (27–40) 29 (23–35) 28 (22–34) 30 (24–37) 1.0
Female 114 61 (51–70) 44 (35–54) 37 (28–47) 34 (26–44) 32 (24–41) 63 (54–72) 47 (38–57) 42 (33–52) 41 (32–51) 40 (31–50) 1.6
C16.9 Unspecified Male 2987 42 (40–44) 29 (27–31) 24 (22–26) 21 (20–23) 20 (19–21) 45 (43–47) 34 (32–36) 30 (28–32) 30 (28–32) 31 (29–33) 0.9

















Table 6 Survival rate of patients with gastric cancer stratified by age and stage during 2002–2003 in Shanghai, China
Age (years) Stage* N Observed survival rate [% (95% CI)]
1 year 2 years 3 years 4 years 5 years
35-44 I 44 95 (83–99) 88 (74–95) 86 (72–94) 81 (66–91) 81 (66–91)
II 77 89 (79–95) 76 (65–85) 72 (60–81) 69 (57–79) 69 (57–79)
III 80 71 (60–80) 51 (40–62) 41 (30–53) 36 (26–48) 32 (22–43)
IV 95 22 (14–32) 12 (7–21) 5 (2–12) 4 (1–11) 3 (1–9)
45-54 I 127 98 (93–100) 93 (87–97) 87 (80–92) 83 (75–89) 82 (74–88)
II 221 89 (84–93) 74 (68–80) 68 (61–74) 61 (54–67) 59 (52–65)
III 244 74 (68–79) 52 (46–58) 43 (37–49) 39 (33–45) 36 (30–42)
IV 264 33 (27–39) 20 (15–25) 18 (14–23) 15 (11–20) 14 (10–19)
55-64 I 126 90 (83–94) 86 (78–91) 82 (74–88) 80 (72–86) 78 (70–85)
II 225 80 (74–85) 70 (63–76) 62 (55–68) 59 (52–65) 56 (49–63)
III 243 60 (54–66) 40 (34–46) 32 (26–38) 27 (22–33) 26 (21–32)
IV 242 35 (29–41) 17 (13–22) 12 (8–17) 9 (6–14) 9 (6–14)
65-74 I 207 87 (81–91) 76 (69–82) 69 (62–75) 67 (60–73) 64 (57–70)
II 354 75 (70–79) 61 (56–66) 52 (47–57) 49 (44–54) 45 (40–50)
III 469 61 (56–65) 43 (38–48) 32 (28–36) 29 (25–33) 27 (23–31)
IV 492 29 (25–33) 16 (13–20) 11 (8–14) 9 (7–12) 7 (5–10)
75-84 I 82 77 (66–85) 57 (46–68) 45 (34–56) 37 (27–48) 31 (22–42)
II 175 70 (63–77) 50 (42–58) 36 (29–44) 31 (24–39) 26 (20–33)
III 276 46 (40–52) 26 (21–32) 21 (16–26) 18 (14–23) 17 (13–22)
IV 345 21 (17–26) 12 (9–16) 9 (6–13) 6 (4–9) 5 (3–8)
*Cases with unknown stages were not involved in the analysis.
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(Table 4).
Tumor sites and survival rate
Survival rate of gastric cancer varied among different
tumor sites. The worst prognosis was observed in pa-
tients with cardia cancer, as the 5-years relative survival
rate was only 29% (Table 5).
Stratification analysis by age and stage
In each age group, the 5-years survival rate declined
with the increase of tumor stages. For patients at stage I
and II, the 5-year survival rates were higher among those
aged 35–44 years (81% and 69%, respectively). For pa-
tients at stage III–IV, the 5-year survival rates were
higher among those aged 45–54 years (36% and 14%,
respectively) (Table 6).
Long-term trends of survival rate
The trends of long-term survival data were available for
patients spanning in the four time periods (1972–1976,
1980–1984, 1988–1991, and 2002–2003). An obvious in-
creased trend of survival probability could be found dur-
ing the last decades in either male or female patients
(Figures 1 and 2). For example, gastric cancer patientsdiagnosed during 1972–1976 had a 5-years relative sur-
vival rate at 12% for males and 11% for females, respect-
ively, which dramatically increased to 30% for male and
32% for female patients respectively during the period of
2002–2003 (Table 7).
Discussion
In this longitudinal study of gastric cancer based on
Shanghai Cancer Registry database, we observed a de-
clining trend of survival probability with the increase of
patient’s age and clinical stages at the time of diagnosis.
Long-term survival of gastric cancer varied among dif-
ferent tumor sites. The worst prognosis was observed in
patients with cardia cancer. By using a long-term sur-
vival analysis on the longitudinal survival data from
1972 to 2003, we depicted that the survival probability
of patients with gastric cancer in Shanghai has improved
significantly during the last decades.
Gastric cancer remains a major public health issue
ranking the fourth most common cancer and the second
leading cause of cancer death worldwide [4]. National
mortality surveys conducted in 1970s and 1990s in
China, revealed an obvious cluster of geographical distri-
bution of gastric cancer in the country, with the highest
mortality mostly locating in rural areas, especially in the
Figure 1 Observed and relative survival rate of male gastric cancer patients.
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slight increase from the 1970s to the early 1990s, re-
markable declines in gastric cancer mortality were no-
ticed in almost the entire population in China. These
declines were largely due to the dramatic improvements
in the social-economic environment, lifestyle, nutrition,
education, and health care system after economic re-
forms started decades ago [12]. Nevertheless, gastric
cancer remains a cancer burden currently and be one of
the key issues in cancer prevention and control strategy
in China [12,13].
Data from this study revealed that the survival rate of
gastric cancer patients in Shanghai was still poor. It was
a little higher than that of America and some European
countries [14-16], but much lower than that in Japanand Korea [17-19]. In this study, we used both observed
survival rate and relative survival rate to estimate the
prognosis of gastric cancer. Relative survival rate which
is calculated by dividing observed survival rate by
expected survival rate is designed for cancer survival
studies, in order to exclude the effect resulting from dif-
ferent background mortalities. The 5-years relative sur-
vival rate is commonly used to monitor the progress of
cancer and it reasonably indicates the average survival
experience of cancer patients in a given population [20].
During the last decades over the four observation pe-
riods of 1972–1976, 1980–1984, 1988–1991, and 2002–
2003, the 5-years relative survival rate of gastric cancer
increased from 12% to 30% among male patients and
from 11% to 32% among female patients, which seemed
Figure 2 Observed and relative survival rate of female gastric cancer patients.
Zheng et al. BMC Cancer 2014, 14:300 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/300to be more significant than those observed in the
European countries [21].
Gender difference of long-term survival of gastric can-
cer was not obvious in Shanghai, which was similar to
the findings from other studies [22]. The prognosis of
gastric cancer is closely related to the stage of disease at
diagnosis. In stage I, cancer has formed in the inside lin-
ing of the mucosa (innermost layer) of the stomach wall,
whereas in stage IV, cancer has spread to distant parts of
the body. Early gastric cancer, whereby disease is limited
to mucosa and submucosa, confers a survival rate of
greater than 90% in 5 years in many centers [23]. Our
study further proved that the detection of gastric cancer
in the early stage is vitally important in ensuring an ex-
cellent prognosis. Every effort needs to be made to facili-
tate the early diagnosis of gastric cancer with aims to
prolong patient’s survival time and quality of life [23].
Epidemiologic evidence supports the classification ofgastric cancer into two biologically distinct disease en-
tities, those occurring proximally (cardia) and distally
(noncardia). Though carcinomas of the cardia and stom-
ach are frequently grouped together in epidemiologic
statistics, they are clearly distinct diseases [24]. Epi-
demiological and clinical studies have led some authors
to suggest that tumors located at the esophageal-gastric
junction are distinct from other tumors located in the
esophagus or distal stomach, with differing risk factors,
tumor characteristics, and biological behavior [25,26].
The association between tumor located at the esophageal-
gastric junction and more advanced disease stage has been
reported elsewhere and some authors have attributed
these findings to more aggressive behavior of junctional
tumor [26]. Junctional tumors are associated with adverse
prognosis compared with other esophageal and gastric
cancers. The anatomical site of these tumors potentially
allows tumor spread to lymph nodes located above or
Table 7 Comparison of survival rate of patients with gastric cancer from 1972 to 2003 in Shanghai, China
Sex Year N Observed survival rate [% (95% CI)] Relative survival rate [% (95% CI)]
1 year 2 years 3 years 4 years 5 years 1 year 2 years 3 years 4 years 5 years
Male 1972-1976 8287 40 (39–41) 22 (21–23) 15 (14–16) 12 (11–13) 10 (9–11) 41 (40–42) 24 (23–25) 17 (16–18) 13 (12–14) 12 (11–13)
1980-1984 9484 40 (39–41) 26 (25-270 21 (20–23) 18 (17–19) 16 (15–17) 41 (40–42) 28 (27–29) 23 (22–24) 20 (19–21) 19 (18–20)
1988-1991 8134 42 (41–43) 29 (28–30) 24 (23–25) 22 (21–23) 20 (19–21) 44 (43–45) 31 (30–32) 27 (26–28) 25 (24–26) 24 (23–25)
2002-2003 7038 51 (50–52) 37 (36–38) 30 (29–31) 27 (26–28) 25 (24–26) 54 (53–55) 40 (39–41) 34 (33–35) 31 (30–32) 30 (29–31)
χ2* 135.90 266.87 378.96 444.63 485.62 - - - - -
P* <0.001 <0.001 <0.001 <0.001 <0.001 - - - - -
Female 1972-1976 3860 38 (36–40) 20 (19–21) 14 (13–15) 11 (10–12) 10 (9–11) 39 (38–41) 21 (20–22) 15 (14–16) 12 (11–13) 11 (10–12)
1980-1984 4507 38 (37–39) 24 (23–25) 19 (18–20) 17 (16–18) 15 (14–16) 38 (37–39) 25 (24–26) 20 (19–21) 18 (17–19) 17 (16–18)
1988-1991 4224 39 (38–40) 27 (26–28) 22 (21–23) 20 (19–21) 19 (18–20) 40 (39–42) 28 (27–29) 24 (23–25) 23 (22–24) 22 (21–23)
2002-2003 3871 52 (50–54) 38 (36–40) 32 (31–34) 30 (29–31) 27 (26–28) 56 (54–58) 42 (40–44) 37 (36–39) 34 (33–36) 32 (31–34)
χ2* 154.65 277.26 308.62 344.42 316.50 - - - - -
P* <0.001 <0.001 <0.001 <0.001 <0.001 - - - - -
*Logrank test was used to compare the survival rates.
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cated in cardia are more aggressive than the ones of distal
stomach, and the former ones are usually diagnosed at ad-
vanced stage [28,29]. Our study also demonstrated this
situation that the 5-years relative survival rate of cardia
cancer was the lowest compared with other tumor sites.
One strength of our study was that the databases were
acquired from the Shanghai Cancer Registry, the oldest
population based cancer registry in mainland China. The
registry has contributed data on survival from cancer sites
or types registered during 1988–1991 to the first volume of
IARC publication on Cancer. Survival data obtained from a
population-based cancer registry ideally portrays the aver-
age outcome of the disease which avoids the selective bias
commonly appears in hospital sourced cases. Comparing to
clinical survival study providing information about the
treatment, the population-based survival study can evaluate
the effectiveness of healthcare systems [30,31]. Besides,
population-based cancer registration is necessary to moni-
tor cancer incidence and estimate cancer prevalence [32].
One limitation of this study is that there were 58.4%
patients reported with unknown stages. It might be at-
tributed to missing information or patients with unre-
sected cancers. If these cases with unknown stages were
gastric cancer patients unable to be surgically resected
(so, without TNM stage), usually the survival rate was
not far from that of patients with stage IV cases. In this
study, their survival was not far from that of stage III,
suggesting that most of cases correspond to missing in-
formation. Unfortunately, we couldn’t distinguish them
based on the current database because all these patients
were registered as NOS in the notification cards re-
ported 10 years ago. Secondly, it has been reported that
cancer site-related factors may influence the outcome.
However, due to the retrospective nature of the presentstudy, we failed to obtain all the needed information for
the sites which could have contributed to the bias in es-
timating the survival rate and thus the influence on the
outcome. Thirdly, in the present study, we chose the
“classical” relative survival method for cancer survival
estimation which may not correctly estimate the net sur-
vival, whenever a factor influences jointly the mortality
due to cancer or the population life tables used for
other-cause mortality. The “net” survival developed by
Pohar et al. might be an alternative way used in the fu-
ture to replace the relative survival in population-based
studies [33].
Conclusions
In conclusion, the survival probability of patients with
gastric cancer in Shanghai has improved significantly
during the last decades. Age, stage and site of tumor
have impacts on patient’s prognosis. Information from
this study is useful for understanding survival differences
that are influenced by changing prevention and treat-
ment strategies.
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